Aemetis, Inc. (NASDAQ:AMTX) Receives $12.95 Average PT from Analysts

Aemetis, Inc. (NASDAQ:AMTX) has been given a consensus rating of “Moderate Buy” by the five analysts that are currently covering the firm, MarketBeat reports. One equities research analyst has rated the stock with a hold rating and four have issued a buy rating on the company. The average 1-year target price among brokerages that have issued ratings on the stock in the last year is $12.95.

A number of equities analysts recently issued reports on AMTX shares. Ascendiant Capital Markets lowered their price target on Aemetis from $20.00 to $19.00 and set a “buy” rating on the stock in a report on Tuesday, September 3rd. HC Wainwright reaffirmed a “buy” rating and set a $28.00 price target on shares of Aemetis in a report on Friday, November 15th. Finally, UBS Group dropped their target price on Aemetis from $8.25 to $7.75 and set a “buy” rating on the stock in a research report on Monday, August 19th.

Aemetis Price Performance

Aemetis stock opened at $3.01 on Thursday. The stock has a market cap of $149.72 million, a PE ratio of -1.33 and a beta of 1.35. The stock’s fifty day moving average is $3.29 and its two-hundred day moving average is $3.02. Aemetis has a 1-year low of $2.10 and a 1-year high of $7.03.

Aemetis (NASDAQ:AMTX) last released its quarterly earnings results on Tuesday, November 12th. The specialty chemicals company reported ($0.38) EPS for the quarter, topping the consensus estimate of ($0.47) by $0.09. The firm had revenue of $81.44 million for the quarter, compared to analyst estimates of $77.79 million. During the same period last year, the firm earned ($0.59) EPS. On average, research analysts expect that Aemetis will post -2.02 earnings per share for the current fiscal year.

Institutional Trading of Aemetis

A number of institutional investors and hedge funds have recently added to or reduced their stakes in AMTX. Bank of New York Mellon Corp purchased a new position in Aemetis in the second quarter worth $306,000. Rhumbline Advisers grew its stake in shares of Aemetis by 2,837.1% in the second quarter. Rhumbline Advisers now owns 52,309 shares of the specialty chemicals company’s stock worth $157,000 after purchasing an additional 50,528 shares during the last quarter. Hutchinson Capital Management CA purchased a new position in Aemetis during the 2nd quarter valued at about $70,000. Susquehanna Fundamental Investments LLC raised its position in Aemetis by 287.4% during the 2nd quarter. Susquehanna Fundamental Investments LLC now owns 126,078 shares of the specialty chemicals company’s stock valued at $379,000 after purchasing an additional 93,536 shares during the last quarter. Finally, FMR LLC increased its position in Aemetis by 68.2% during the 3rd quarter. FMR LLC now owns 22,531 shares of the specialty chemicals company’s stock valued at $52,000 after purchasing an additional 9,137 shares during the period. Institutional investors and hedge funds own 27.02% of the company’s stock.

Aemetis Company Profile

Aemetis, Inc operates as a renewable natural gas and renewable fuels company. It operates through three segments: California Ethanol, California Dairy Renewable Natural Gas, and India Biodiesel. The company focuses on the operation, acquisition, development, and commercialization of technologies to produce low and negative carbon intensity renewable fuels that replace fossil-based products.